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Renal transplantation has undoubtedly become the therapy of 
choice for children with end-stage renal failure,1 allowing them 
to return to a fairly normal way of life at home and to return 
to school. However paediatric renal transplant programmes 
have many challenges especially in a developing country. 
Optimising renal allograft survival is important because of 
limited resources to treat irreversible renal failure.2,3 Paediatric 
numbers remain low compared with adult programmes 
and contribute approximately 2% of any national dialysis 
programme.4
Patients and methods
A retrospective folder review was done of all patients < 16 
years old who received renal transplants at Red Cross War 
Memorial Children’s and Groote Schuur Hospitals’ combined 
Transplant Unit from August 1968 to April 2006. The first 
paediatric transplant was performed in August 1968 and to 
date 149 renal transplants have been performed in 132 patients. 
Eighty-nine (60%) transplants have been performed in the 
last 10 years (1995 - 2005). The number of paediatric renal 
transplants per year is shown in Fig. 1.
Fourteen children received 2 grafts, 2 children 3 grafts and 1 
child 4 grafts (2 at another centre). Gender distribution was 67 
males and 65 females, who ranged in weight from 8 kg to 63 
kg. Thirty-five (24%) received grafts from living related donors 
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Introduction. Renal transplantation is the therapy of choice 
for children with end-stage renal failure. There are many 
challenges associated with a paediatric programme in a 
developing country where organs are limited.
Methods. A retrospective review was undertaken of 149 
paediatric renal transplants performed between 1968 and 2006 
with specific emphasis on transplants performed in the last 10 
years. Survival of patients and grafts was analysed and specific 
problems related to drugs and infections were reviewed.
Results. On review of the total programme, 60% of the 
transplants have been performed in the last 10 years, with 
satisfactory overall patient and graft survival for the first 8 
years post transplant. At this point, transfer to adult units with 
non-compliance becomes a significant problem. 
Rejection is less of a problem than previously but 
infection is now a bigger issue – specifically tuberculosis 
(TB), cytomegalovirus (CMV) and Epstein-Barr virus (EBV) 
infections with related complications. A wide variety of drugs 
are available for tailoring immunosuppression to minimise 
side-effects.
Conclusion. It is possible to have a successful paediatric 
transplant programme in a developing country. However, 
to improve long-term outcomes certain issues need to be 
addressed, including reduction of nephrotoxic drugs and 
cardiovascular risk factors and providing successful adolescent 
to adult unit transition.
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Fig. 1. Number of paediatric renal transplants by year.
Living related
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and 114 (76%) were cadaveric transplants. Age at the time of 
transplant is shown in Fig. 2.
Four combined liver-kidney transplants were performed, 3 
for primary hyperoxaluria and 1 for polycystic kidney disease 
with hepatic fibrosis. These patients have currently survived 
between 2 and 6 years post transplant and all have adequate 
graft function. Causes of renal failure are shown in Table I.
HLA matching is not ideal and often 5 or more mismatches are 
present. 
Our first-line immunosuppression remains cyclosporin, 
azathioprine and prednisone, but we do have the ability to 
tailor immunosuppression to suit individual patients. Other 
drugs used include tacrolimus (Prograf/FK), mycophenolate 
mofetil (MMF) and sirolimus (Rapamycin). We use steroids 
and wean to 2.5 mg on alternate days (or 0.05 mg/kg/day) as 
the lowest dose – no complete steroid withdrawal or steroid 
avoidance is practised.
Induction agents (basiliximab, daclizumab) in the form 
of interleukin (IL) 2 receptor blockers have been used and, 
for cost containment, we have used daclizumab for smaller 
children (9 cases) and basiliximab for bigger children (7 cases). 
Acute rejection has been biopsy proven and then treated 
with ‘pulsed’ intravenous methylprednisolone in dosing of 10 
mg/kg/dose for 3 - 4 doses followed by increased oral steroids.
Complications resulting in graft loss have included rejection 
(1 graft lost due to hyperacute rejection) and surgical problems 
(2 cases of vascular thrombosis), with infections remaining the 
biggest problem.
Tuberculosis (TB) is endemic in our region (638 cases/ 
100 000 population) and often presents late. During transplant 
workup, every patient is screened for TB (history of contact or 
previous TB, skin testing, gastric washings for bacilli and chest 
X-ray) and prophylaxis is not routinely used. Epstein-Barr 
virus (EBV) and cytomegalovirus (CMV) infections also remain 
a major issue. Identification of CMV and EBV status of both 
donor and recipient is performed and where necessary 2 weeks 
of intravenous ganciclovir prophylaxis is administered.  
Vaccinations that have been added to our routine 
immunisations schedule (polio, haemophilus b, diphtheria, 
pertussis, tetanus, hepatitis B) include hepatitis A and varicella 
zoster. Adequate immunisation prior to transplant is important 
with continued surveillance of non-live vaccines on a regular 
basis post transplantation.  
Adolescent issues include our current adolescent cut-off 
age of 13 years after which the patients are transferred to an 
adult renal service in large referral hospital. This part of the 
programme produces most of the compliance issues with 
recent action implemented including preceding psychosocial 
input and transition at older age (Fig. 3).
Statistics. Kaplan Meier plots were used for calculating 
patient and graft survival.
Results
Survival figures 
In the last 10 years we have performed 89 paediatric renal 
transplants; 68 patients are being followed up locally. Notably 
we are following up 38 patients who are ‘over age’ according to 
our cut-off of 13 years (see Fig. 3).
Graft survival for the overall programme is 72% at 1 year 










Fig. 2. Age at time of transplant.
Primary disease Frequency (%)
Glomerulonephritis 19
Renal dysplasia 18
Posterior urethral valves 16
Reflux nephropathy 12
Systemic lupus erythematosis 9
Polycystic kidney disease 7
Glomerulosclerosis 7
Other 12
Table I. Causes of renal failure in 149 transplanted children
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91% at 1 year and 80% at 5 years, but then starts dropping off 
at 7 years to 72% (Figs 4 and 5). Patient survival during this 
period is 96% at 1 year and 88% at 5 years.
This compares favourably with paediatric figures elsewhere; 
patients transplanted from 1993 to 1995 in the UK5 have a 1-
year graft survival of 79% and a 5-year survival of 68%, and 
North American6 5-year graft survival was 73% for cadaveric 
and 81% for living-donor recipients over the same time period.
Mortality in the group transplanted in the last 10 years  
(1995 - 2005) was 8/89 (9%). Causes of death include sepsis in  
3 cases (2 of CMV and 1 of Gram-negative sepsis), recurrence 
of primary disease in 2 (focal segmental glomerulosclerosis), 
non-compliance with chronic rejection in 3 and hepatitis B 
infection in 1. 
Surgical complications were few and included vascular 
thrombosis leading to graft loss in 2/89 cases (2.3%), 
ureteric leak in 1 case (successfully repaired), and 3 cases 
of vesicoureteric reflux (VUR) with recurrent urinary tract 
infections (requiring re-implantation of ureter).
In the light of our small donor pool3 the HLA matching of 
our cadaver transplants in our paediatric patients was poor, 
with 60/89 (68%) of our patients having 5 or more mismatches 
out of 6.
Immunosuppression
Drugs used by our patients include azathioprine (40%), 
tacrolimus (25%), cyclosporin (24%), MMF (6%) and Rapamycin 
(5%). We have used similar proportions of both cyclosporin 
(49%) and tacrolimus (51%). Cyclosporin is significantly cheaper 
than tacrolimus and for cost-effectiveness this has been our first-
line agent. In our paediatric patients on cyclosporin, cosmetic 
side-effects including hirsutism and gum hypertrophy have 
been significant problems. This together with rejection episodes 
has resulted in conversion to tacrolimus in individual cases. 
Tacrolimus was implicated in diabetes mellitus in 8/131(6%) 
paediatric transplants (5 renal and 3 liver) currently being 
followed-up by our unit. Mean age at transplant was 10 years 
4 months and mean age at diagnosis 11 years. Patients who 
developed diabetes had common risk factors: high body mass 
index, previously high dosage of steroids and high mean trough 
tacrolimus level of 10.4 ng/ml. There was also an increased 
incidence in our black patients  – 4/8 (50%) patients who 
developed diabetes were black despite this group being only 
28/89 (31%) of our total programme.
MMF is increasingly being used as a calcineurin-sparing 
agent but diarrhoea has been a significant problem especially 
in adolescent patients. If tolerated, we have reduced our 
cyclosporin to achieve trough levels less than 50 ng/ml and 
tacrolimus to less than 5 ng/ml. In 3 cases we have successfully 
stopped calcineurin drugs and have maintained their grafts on 
MMF and low-dose alternate-day steroids only.
Rapamycin has also been used as a calcineurin-sparing agent 
but we have seen many of the side-effects described including 
high cholesterol (50%), interstitial pneumonitis (2 cases), severe 
bone-marrow suppression with thrombocytopenia and bleeding 
tendency (1 case) and proteinuria (2 cases). We have not had 
problems of delayed wound healing, as we have not used this 
agent in the early post-transplant period.
 IL2 receptor blockers have been increasingly used as 
induction agents, especially in view of our poor HLA matching. 
This resulted in an acute rejection rate of only 3/16 (18.8%) 
compared with historic controls of 16/23 (70%). There has 
therefore been a significantly overall shorter stay in hospital 
with the potential to use lower doses of steroids. Long-term 
graft survival still remains to be seen. When comparing the 
drugs used, no rejection was noted in 4/7 cases on basiliximab 
and 9/9 cases on daclizumab, suggesting that daclizumab in 
our setting appears to have a better outcome, but this needs 
larger studies.  
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TB represents a significant problem. During the period  
1996 - 2004, the incidence of TB was 7/72 (9.7%) in our 
transplant patients. Presentation was 10 months to 8 years 
post transplant with symptoms of fever and cough in all and 
weight loss in most. No patients were on prophylaxis. With 
the exception of one renal case, the rest all had pulmonary TB 
with pericardial involvement in 2 cases. Immunosuppression 
at the time of diagnosis consisted of cyclosporin, azathioprine 
and prednisone.  Diagnosis was made on finding acid-fast 
bacilli using a combination of sputum, nasogastric aspirate 
and bronchial lavage. In one case, a fine-needle aspirate of the 
lung produced the acid-fast bacilli. All the cases were typically 
mycobacterium TB and fully sensitive to rifampicin and 
INH.  Three cases had had an increased dose of steroids in the 
preceding 3 months. An increased cyclosporin dose (up to 5 
times) was required once starting the rifampicin. All cases were 
successfully treated with no loss of patient or graft. 
Fatal CMV infection was seen in a 13-year-old girl with 
renal dysplasia and Fanconi’s anaemia who received a 
CMV-mismatched organ (donor CMV positive: recipient 
CMV negative) in February 2001. Prophylactic intravenous 
ganciclovir was given for 2 weeks, but unfortunately she 
developed a pneumonia requiring ventilation 11 months later 
and died of CMV pneumonia.  
EBV-driven post-transplant lymphoproliferative disorder 
(PTLD) was seen in 1 renal transplant who presented with a 
nodal mass in his inguinal region. Immunosuppression was 
reduced and ganciclovir and rituximab (anti-CD 20 agent) were 
given together with chemotherapy. Therapy remains successful 
together with preserved renal function.
Other serious infections in this group of patients have 
included disseminated varicella with transverse myelitis, 
Pneumocystis jiroveci pneumonia and cat scratch disease 
(Bartonella henselae). All were treated successfully and retained 
their grafts. 
Vaccinations
Audit of vaccination status in a group of 32 cases with age 
range 93 - 225 months (mean 148 months) reviewed post 
transplant found protective immunity to hepatitis A (53% 
patients), hepatitis B (19% patients) and varicella (72% 
patients). 
Adolescent transplant transition
We have had difficulty with transition of adolescents to adult 
units in the last 10 years with 5 adolescents having lost their 
grafts and 2 dying within 1 year of transfer despite adequate 
renal function at time of transfer. We have good 1- and 5-year 
graft and patient survival but our long-term outcome in the 
adolescent age group is significantly worse than in younger 
transplant recipients, as is reported universally.
Discussion
Paediatric transplantation poses numerous challenges, not only 
the conventional problems of acute rejection and infection, but 
also technically creative surgery to accommodate the significant 
size range (our group ranged from 8 kg to 63 kg) of paediatric 
patients. There may be further challenges in a developing 
country including difficult social circumstances, poor HLA 
matching (68% of our patients had 5 or more mismatches) as 
well as a limited number of donors exacerbated by the high 
incidence of HIV infection. In order to try and increase our 
donor pool, we may need to expand the current pool of living 
related donors (24%) beyond just the parents and potentially 
also consider non-heart-beating donors.
Whereas previously acute rejection was our biggest concern, 
this has now become easier to manage, by using the newer 
immunosuppressant agents including induction with IL2 
receptor blockers. Our acute rejection rate has reduced to 18.8% 
using 2 initial doses of IL2 receptor blockers (both basiliximab 
and daclizumab used in 2-dosing regimen). Despite the initial 
cost of this form of therapy, these agents have allowed us to 
use an overall cheaper immunosuppressive protocol (such 
as cyclosporin and azathioprine) in our setting where cost 
containment is important. 
However, the consequences of increased immunosuppression 
and reduced rejection are increased infection; this is highlighted 
by problems such as CMV infection or EBV-driven PTLD. This 
is particularly a problem in the young patient with no previous 
CMV or EBV exposure who receives a donor organ-recipient 
mismatch. The advent of qualitative and, more recently, 
quantitative polymerase chain reaction (PRC) testing will have 
a significant impact on both monitoring and management 
of these viruses. Intravenous ganciclovir is costly and 
inconvenient and hopefully prophylaxis will be made easier 
with the introduction of the oral valganciclovir form. As yet no 
vaccines are available for these two viruses.
TB is endemic in our region – our rate of TB in paediatric 
transplant patients was 9.7% – and together with HIV infection, 
raises issues of drug resistance, choice and duration of 
prophylactic agents.6 Our patients developed TB 10 months 
to 8 years post transplant and it would thus be futile using 
prophylaxis for TB in the first 6 months only. Drug interactions 
between anti-TB drugs and immunosuppressants are also a 
concern.
On review of the vaccination status in a small group of 
our patients, hepatitis B levels were low post transplant with 
Varicella rates best overall. Paediatric studies have shown loss 
of antibodies to vaccinations within 6 months post-transplant.7 
Awareness of adequate vaccination pre-transplant, specifically 
live-attenuated vaccines, with regular post-transplant 
monitoring, is important in reducing complications from these 
infections.
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In an established paediatric programme, with 1- and 5-year 
results which are  satisfactory by international paediatric 
standards, despite all the problems of a developing country, 
emphasis on long-term graft and patient survival becomes 
an important focus. In view of this, we have tried to limit 
nephrotoxicity often caused by calcineurin inhibitors by using 
renal-sparing immunosuppressants. MMF has been useful 
in reducing dosing or even ceasing calcineurin inhibitors 
completely in those with chronic allograft nephropathy8 and 
we have managed to use MMF and steroids as dual therapy 
only, with stable renal function so far in 3 of our patients. 
Sirolimus has also been well described as a renal-sparing 
agent,9 but we have seen a significant number of drug-
related side-effects including interstitial pneumonitis and 
thrombocytopenia with purpura. In 2 cases we have noticed 
unexplained new-onset proteinuria, which has been described 
by a few centres as a concern. 
In those patients on calcineurin inhibitors, cyclosporin has 
been responsible for significant cosmetic effects (hirsuitism and 
gum hypertrophy). These patients have usually been changed 
to tacrolimus therapy but this has also had problems of 
diabetes in 6% of our renal transplant in which 50% were black 
paediatric patients (relatively higher incidence than that of the 
total programme which consists of 31% black patients).
Children’s growth in paediatric transplantation has received 
much attention recently and this is particularly important at a 
centre where growth hormone is not easily available. Steroids 
as immunosuppression have attracted negative press recently. 
In response to this, there have been three main approaches: (i) 
steroid elimination or avoidance in the first place12 with use 
of heavier immunosuppression such as a prolonged course of 
daclizumab; (ii) steroid withdrawal in those who had steroids 
at time of transplant;13 or (iii) steroid preservation at low 
dosing. We use the last approach using low-dose (0.05 mg/
kg/day) alternate-day steroids. A recent review by Marks and 
Trompeter14 also encouraged steroid preservation to prevent 
exchanging acute rejection for infection including EBV/
PTLD. They suggest that steroids remain superior to many 
other immunosuppressive drugs in terms of cost and past 
experience, suggesting that it may be more sensible to remove 
calcineurin inhibition.
Long-term outcomes are greatly affected by adolescent 
issues and this is clearly seen by our results at 1 and 5 years 
compared with the group more than 7 years post transplant 
(Figs 4 and 5). This is notoriously the most difficult group 
of patients to follow up, a problem for colleagues in both 
paediatric and adult units alike, and we have this in common 
with the rest of the world.15 This is particularly problematic 
where resources are limited, with adolescent issues similar 
to those in developed countries, but different economic 
constraints resulting in patients not being offered repeat 
dialysis or transplant.  
In response to our poor long-term graft survival in 
adolescence, we have set up a combined transplant clinic with 
our adult and paediatric team based at the adult unit. This 
includes social support in the form of psychiatrists, nurses and 
social workers. 
Challenges in the transition period include overcoming the 
fear of an unknown hospital, adjusting to a different patient/
doctor ratio and increased independence in terms of their own 
health care. The move is preceded by psychological input in 
the form of workshops and one-to-one interviews prior to 
transfer to the adult unit. 
We also delay the transfer to at least 16 years of age and 
often even older until patients are mature enough to do the 
transition with their independence established. Preparation of 
our younger adolescents, involving them in their own renal 
function results and medication adjustments, is also important 
with a positive goal of seeing transition to an adult unit as 
a successful ‘graduation’ process. A ‘champion’ on the adult 
service is required – be that a nurse or a doctor – so that the 
patients feel comfortable at the time of transfer by identifying 
a familiar face involved with them throughout the transition 
period.
Other factors affecting long-term outcome also depend on 
decreasing cardiovascular risk factors by reduction of steroid 
dosing, careful attention to body mass index to prevent obesity 
and inclusion of statins where necessary.
Despite all the challenges of a developing country, a 
successful paediatric transplant programme is possible, 
provided one is aware of all the pitfalls including infection, 
nephrotoxic drugs and adolescent transition.
Thanks to Jeanette Raad for statistical assistance.
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